N.B. the English version below is an office translation. In case of any discrepancy between the Swedish and the English version, the Swedish version shall prevail. The following resolutions, among others, were adopted by the annual general meeting of Hansa Medical AB (publ) held on 2 June 2015. Dividend The annual general meeting resolved that no dividend will be paid for the financial year 2014. Discharge from liability The annual general meeting granted the directors and CEO discharge from liability in respect of the 2014 financial year. Board of directors and auditor The annual general meeting resolved to re-elect Birgit Stattin Norinder, Anders Blom, Stina Gestrelius, Per Olof Wallström and Cindy Wong as Board members and to elect Hans Schikan as Board member. Birgit Stattin Norinder was re-elected as chairman of the Board. The annual general meeting resolved to elect KPMG AB in Malmö as the company’s auditor. Dan Kjellqvist, the Company’s former auditor, will be auditor-in-charge. Hans GCP Schikan, born 1958. Pharmacist, Utrecht University. Other appointments: Supervisory Board member of Prosensa, The Netherlands. Board member of Swedish Orphan Biovitrum AB (publ) and Top Team Dutch Top Sector Life Sciences & Health. Member of the Biotechnology Industry Organization’s Emerging Companies Section Governing Board. Member of the Advisory Board of BioScience Park Leiden. Previous appointments: CEO of Prosensa. Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme. Board member of Top Institute Pharma. The annual general meeting resolved on remuneration to the Board as follows. Remuneration to the Board members: SEK 300,000 to the Chairman of the Board and SEK 100,000 each to the other Board Members except for Anders Blom. Remuneration to the Board committees: SEK 40,000 to the chairman and SEK 30,000 each to the other Board Members in the audit committee, SEK 40,000 to the chairman and SEK 25,000 each to the other Board Members in the Remuneration Committee and SEK 25,000 each to the Board Members in the Scientific Committee. A Board Member may, if it is in accordance with current tax legislation and provided that it is cost neutral for the company, be given the possibility to invoice the remuneration from his own company, provided that the company is registered for corporate tax (sw. F-skatt). Social contributions fees and VAT will be added to such remuneration invoiced by Board Member within a business operation. The annual general meeting furthermore resolved on remuneration to the auditor according to an authorized account. Resolution on issue of share warrants and approval of transfer of share warrants The annual general meeting resolved on issue of share warrants and approval of transfer of share warrants as follows. The company shall issue a maximum of 400,000 share warrants. The right to subscribe for the share warrants shall, with deviation from the shareholders’ preferential right, be allotted to Cartela R&D AB (the “Subsidiary”), a wholly owned subsidiary of the company. Subscription must be completed no later than 15 June 2015. The share warrants will be issued without consideration. The Subsidiary shall transfer the share warrants according to what is stated below. Each share warrant entitles its holder to subscribe for one new share in the company. Subscription of shares in accordance with the terms and conditions of the share warrants may be made as from 15 June 2018 up to and including 15 June 2019. The subscription price (strike price) will correspond to the market price of an ordinary share at the time of the issuance with an annual increase of 7 percent. This means that the strike price after 3 years will be 122.5 percent of the current market price of a share, and after 4 years it will be 131.1 percent. The starting point shall be the volume-weighted share price during 10 trading days immediately prior to the issuance of the warrants. The increase in the company’s share capital upon full exercise of the share warrants will amount to SEK 400,000, and corresponds to a dilution of approximately 1.2 percent of the total number of shares and the total number of votes in the company. The reason for deviation from the shareholders’ preferential right is to implement this incentive program and that the concerned person shall be rewarded for and work for a value increase of the company’s share. The Subsidiary shall transfer the share warrants on the following terms and conditions: The share warrants shall be offered from the Subsidiary to following three categories of persons employed by the company (including new employees): Category A: CEO. Maximum number of warrants per person: 150,000. Maximum number of warrants to category: 150,000. Category B: Management (maximum 5 persons). Maximum number of warrants per person: 40,000. Maximum number of warrants to category: 150,000. Category C: Other employees (maximum 14 persons). Maximum number of warrants per person: 10,000. Maximum number of warrants to category: 130,000. The share warrants shall be transferred on market terms at a price (premium) established on the basis of a market value calculated by an independent valuation institute using the Black & Scholes valuation model. The value for one warrant has been calculated to SEK 8,40 based on a share price of SEK 36,04. For all participants except for the CEO, the company will make a one-time cash bonus of up to 60 percent of the premium. The total cost for these bonus payments, based on the preliminarily calculated value of the option is maximum SEK 3.0 million, including costs for social security contributions. No other costs in addition to the administrative costs and the one-time cash bonus are expected to occur in relation to the warrant program. The warrants shall be subject to other customary terms, including a right to repurchase at market value if the participant’s employment in the company is terminated. Resolution on authorization of the Board of Directors to issue new shares, warrants or convertible instruments The annual general meeting resolved that the Board of Directors shall be authorized to issue new shares, warrants or convertible instruments on one or more occasions prior to the next AGM, with or without regard to shareholders’ pre-emption rights. The payment of issued shares may be in cash, by non-cash consideration, by set-off or otherwise subject to terms and conditions stated in The Swedish Companies Act, chapter 2 section 5, second paragraph, points 1-3 and 5. The number of shares, warrants or convertible instruments to be issued pursuant to the authorization shall be limited to 10 per cent of the shares from time to time outstanding. If the Board of Directors decides on an issue without regard to shareholders’ pre-emption rights, the reason for deviation from the shareholders’ pre-emption rights shall be for the purpose of expanding the circle of owners, acquire or render possible the acquisition of working capital, increase liquidity in the share, carry out corporate acquisitions, or acquire or render possible the acquisition of capital for corporate acquisitions. In conjunction with resolutions regarding share issues with a deviation from the shareholders’ pre-emption rights, the subscription price shall be on market terms at the time of the adoption of the issue resolution. In addition, the annual general meeting also adopted resolutions regarding instructions for the nomination committee as well as guidelines regarding compensation to senior executives. For further information, please contact: Hansa Medical AB Göran Arvidson, CEO and CFO Mobile: 46 70-390 85 30 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About Hansa Medical AB Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.
Resolutions adopted at the annual general meeting of Hansa
Top 10 Most Recent News Articles
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope
Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...
Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays
A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...
Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Australia Leads TTW's 2027 Global Travel Country List
A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...
Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear
A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...
Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites
A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...
Continue ReadingTop 5 Most Recently Viewed Articles
Hepsiburada's Recent Asset-Backed Securities Issuance Explained
Hepsiburada's Second Issuance of Asset-Backed Securities Hepsiburada, a premier e-commerce platform based in Türkiye, has made headlines with its recent announcement regarding the second issuance of asset-backed securities amounting to TRY 350 million. This move marks a significant step as the company continues to solidify its position in the competitive online...
Continue Reading
Discover SODI's Aroma Scent Phone Case: A New Touch to Tech
SODI Unveils Innovative Aroma Scent Phone Case SODI, a premium Apple accessories brand, has launched an exciting new product on Kickstarter that merges technology with emotional design: the Aroma Scent Phone Case. This innovative case is tailored specifically for the iPhone 16 Pro and iPhone 16 Pro Max, offering users not just protection but also a unique sensory...
Continue Reading
The Impact of Economic Changes on Small Businesses
The impacts of economic change upon the small businesses have always been a subject of discussion because they determine the further development, income, and stability of the company. Whether dealing with uneven interest rates or changes in consumer behaviors, every shift in the economies' landscape comes with some risks and rewards. By observing the economic changes and...
Continue Reading
NANO Nuclear Energy Investors: Important Class Action Notice
Important Update for NANO Nuclear Energy Investors Investors in NANO Nano Nuclear Energy Inc. (NASDAQ: NNE) should be aware of a significant class action lawsuit recently filed in the U.S. District Court. The action targets those who acquired NNE securities, particularly during the specified Class Period. Details of the Class Action This lawsuit has been initiated on...
Continue Reading
Understanding Crimson Tide Plc's Recent Market Disclosure Update
Market Position Disclosure for Crimson Tide Plc Crimson Tide Plc, known for its innovative approaches in the mobile technology sector, has made a significant market position disclosure, highlighting details critical for investors and stakeholders. Such disclosures are essential as they provide insight into the company's integrity in maintaining transparency during trading...
Continue Reading